이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jiangxi Fushine Pharmaceutical 관리

관리 기준 확인 2/4

Jiangxi Fushine Pharmaceutical's CEO는 Jian Hua Bao, Apr2022 에 임명되었습니다 의 임기는 2.17 년입니다. 는 CN¥ 1.03B 가치에 해당하는 회사 주식의 20.12% 직접 소유합니다. 1.03B. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 11.8 년입니다.

주요 정보

Jian Hua Bao

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2.4yrs
CEO 소유권	20.1%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	12.1yrs

최근 관리 업데이트

Recent updates

Is Jiangxi Fushine Pharmaceutical (SZSE:300497) A Risky Investment?

Jun 12

What Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) 26% Share Price Gain Is Not Telling You

May 06

Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Business And Shares Still Trailing The Industry

Feb 27

CEO

Jian Hua Bao (47 yo)

2.4yrs

테뉴어

CN¥1,320,200

보상

Mr. Jian Hua Bao is GM & Chairman of Jiangxi Fushine Pharmaceutical Co., Ltd. from April 2022 and serves as Chairman since August 25, 2012.

리더십 팀

이름	위치	테뉴어	보상	소유권
Jian Hua Bao	GM & Chairman	2.4yrs	CN¥1.32m	20.12% CN¥ 991.9m
Yang Guang	Chief Financial Officer	2.4yrs	CN¥341.40k	0.0088% CN¥ 435.7k
Haipeng Wei	Deputy General	no data	CN¥580.70k	0.0073% CN¥ 358.8k
Xiang Ming Zhang	Deputy General Manager	12.1yrs	CN¥623.20k	0.060% CN¥ 3.0m
Zhen Liang Dai	Deputy General Manager	8.5yrs	CN¥637.50k	0.068% CN¥ 3.4m
Ying Liu	Deputy General Manager	4.9yrs	CN¥678.80k	0.033% CN¥ 1.6m
Wei Dong	Manager of the Sales Department & Member of Supervisory Board	2.7yrs	데이터 없음	데이터 없음
Yinghui Chen	Deputy General Manager	1.5yrs	데이터 없음	0.031% CN¥ 1.5m
Yun Peng	Deputy GM & Secretary	2.4yrs	데이터 없음	0.0066% CN¥ 323.8k

2.5yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: 300497 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jian Hua Bao	GM & Chairman	12.1yrs	CN¥1.32m	20.12% CN¥ 991.9m
Wei Dong	Manager of the Sales Department & Member of Supervisory Board	12.1yrs	데이터 없음	데이터 없음
Yan Li	Independent Director	12.1yrs	CN¥119.00k	데이터 없음
Wen Jun Yu	Director	12.1yrs	CN¥35.10k	3.27% CN¥ 161.2m
Hong Liu	Independent Director	10.3yrs	CN¥119.00k	데이터 없음
Hai Bin Yang	Chairman of Supervisory Board	12.1yrs	데이터 없음	데이터 없음
Rong Wu Cheng	Director	12.1yrs	CN¥734.40k	0.045% CN¥ 2.2m
Ting Ye	Member of Supervisory Board	5.5yrs	데이터 없음	데이터 없음
Dan Ke	Director	4.6yrs	CN¥644.10k	0.65% CN¥ 32.2m
Huiyue Li	Vice Chairman of the Board	no data	데이터 없음	0.044% CN¥ 2.2m

12.1yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 이사회: 300497 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.8 년).

Jiangxi Fushine Pharmaceutical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Jiangxi Fushine Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Recent updates

New major risk - Financial data availability

Second quarter 2024 earnings released: CN¥0.038 loss per share (vs CN¥0.051 loss in 2Q 2023)

New minor risk - Share price stability

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Is Jiangxi Fushine Pharmaceutical (SZSE:300497) A Risky Investment?

What Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) 26% Share Price Gain Is Not Telling You

Jiangxi Fushine Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: CN¥0.37 loss per share (vs CN¥0.26 loss in FY 2022)

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Business And Shares Still Trailing The Industry

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding

Third quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.001 profit in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: CN¥0.051 loss per share (vs CN¥0.03 profit in 2Q 2022)

First quarter 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.05 profit in 1Q 2022)

Third quarter 2022 earnings released: EPS: CN¥0.001 (vs CN¥0.017 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.14 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.017 (vs CN¥0.16 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.29 in 2Q 2020)

Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) announces an Equity Buyback for CNY 200 million worth of its shares.

Jiangxi Fushine Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020

Jiangxi Fushine Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2020 Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.70 (vs CN¥0.71 in FY 2019)

New 90-day low: CN¥13.03

New 90-day low: CN¥13.73

Market pulls back on stock over the past week

New 90-day low: CN¥15.64

Third quarter earnings released

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low: CN¥17.20

Jiangxi Fushine Pharmaceutical Co., Ltd. cancelled the transaction announced on March 30, 2020

New 90-day high - CN¥22.57

Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.06415 billion in funding

Jiangxi Fushine Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 05, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령